Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients
Paris (ots/PRNewswire) - - Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe - The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies Servier, a global pharmaceutical company, today announced that the Committee for ...